Showing results (61-70 of 74) with videos related to
Sort By:
Pageof 8
Genes|January 25, 2025
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesGiandomenico Roviello, Irene De Gennaro, Ismaela Vascotto, et al.Therapeutic Advances in Medical Oncology|October 3, 2022
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysisAntonio Galvano, Luisa Castellana, Valerio Gristina, et al.Cancers|December 11, 2022
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective StudyValerio Gristina, Nadia Barraco, Maria La Mantia, et al.Translational Oncology|December 18, 2020
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort studyEdoardo Francini, Fang-Shu Ou, Stefano Lazzi, et al.Journal of Translational Medicine|February 4, 2023
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancerPier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, et al.Therapeutic Advances in Medical Oncology|March 10, 2023
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancerPier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, et al.NPJ Precision Oncology|April 28, 2026
Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancerDavid D Chen, Anat Zimmer, David D Yang, et al.Frontiers in Oncology|November 30, 2019
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-UpMichele Caraglia, Pierpaolo Correale, Rocco Giannicola, et al.JAMA Network Open|July 22, 2021
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line TherapyEdoardo Francini, Francesco Montagnani, Pier Vitale Nuzzo, et al.JCI Insight|November 3, 2018
Tumor fraction in cell-free DNA as a biomarker in prostate cancerAtish D Choudhury, Lillian Werner, Edoardo Francini, et al.Pageof 8